Pliant Therapeutics, Inc.
PLRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001746473
No open-market purchases or sales by Pliant Therapeutics, Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q2 2026, worth $54.8M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Pliant Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 88 | 2 | 92 | +6 |
| Shares | 30.9M | 57.5K | 31.6M | +817.2K (+2.7%) |
| Value | $416.5M | $776.0K | $222.1M | −$193.6M (−46.6%) |
2 institutions that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Pliant Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| AXA S.A. | 335,032 | $2.35M | 0.01% |
| Soleus Capital Management, L.P. | 240,000 | $1.68M | 0.26% |
| Trexquant Investment LP | 42,004 | $294.0K | 0.01% |
| Barclays PLC | 15,483 | $109.0K | 0.00% |
| UBS Asset Management Americas Inc | 15,199 | $106.5K | 0.00% |
| Dimensional Fund Advisors LP | 13,483 | $95.0K | 0.00% |
| XTX Topco Ltd | 12,725 | $89.0K | 0.04% |
| Occudo Quantitative Strategies LP | 12,473 | $87.0K | 0.01% |
| Nisa Investment Advisors, LLC | 8,000 | $56.0K | 0.00% |
| Acadian Asset Management LLC | 4,090 | $27.0K | 0.00% |
| Amalgamated Bank | 3,844 | $27.0K | 0.00% |
| Amalgamated Financial Corp. | 3,844 | $27.0K | 0.00% |
| Quantbot Technologies LP | 2,200 | $15.0K | 0.00% |
| Lindbrook Capital, LLC | 224 | $2.00K | 0.00% |
| Private Capital Group, LLC | 197 | $1.00K | 0.00% |
| Simplex Trading, LLC | 64 | $0 | 0.00% |
| Captrust Financial Advisors | 40 | $0 | 0.00% |
Sold out (11)
Institutions that held Pliant Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Pentwater Capital Management LP | 60,000 | $810.0K |
| Eventide Asset Management, LLC | 42,499 | $574.0K |
| HRT Financial LP | 39,298 | $530.0K |
| Susquehanna International Group, LLP | 29,103 | $393.0K |
| Jacobs Levy Equity Management, Inc | 14,543 | $196.0K |
| Ergoteles LLC | 10,500 | $142.0K |
| ProShare Advisors LLC | 10,335 | $139.0K |
| Squarepoint Ops LLC | 10,188 | $138.0K |
| MetLife Investment Management | 9,508 | $128.4K |
| Metropolitan Life Insurance Co | 7,310 | $98.7K |
| State of Wyoming | 747 | $10.0K |
Not filed for Q1 2022 yet (2)
Institutions that held Pliant Therapeutics, Inc. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Grace Capital | 57,471 | $776.0K |
| NEXT Financial Group, Inc | 20 | $0 |